Biosimilars play a critical role in lowering drug prices. Kaiser Permanente successfully uses biosimilars to improve affordability for our members. We are eager to share best practices and work with policymakers to help facilitate a more competitive market for biologic…
The Medicaid Drug Rebate Program (MDRP) requires pharmaceutical manufacturers to issue rebates to Medicaid for covered outpatient drugs. When they offer prescription drug benefits, Medicaid programs must cover nearly all drugs, potentially reducing Medicaid’s leverage to negotiate discounts. Policymakers created…
The arrival of the novel coronavirus has raised unprecedented challenges across the globe. In our collective effort to help flatten the curve of this pandemic, we are making substantial changes to our daily lives. Physical distancing policies currently in place…
Pharmaceutical marketing aims to shape both patient and clinician perceptions about a drug’s benefit and can significantly impact patient and clinician decisions that then affect outcomes, in addition to draining government and health care system resources. This paper describes the…
As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is important for policymakers to understand the distinct differences between broad categories of therapies as they examine potential solutions. This paper…
Biologics — drugs derived from living organisms that are used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and some cancers — are the fastest growing component of prescription drug spending. While some of these drugs have fostered significant…
© 2022 Kaiser Permanente
Website developed by Kaiser Permanente Northern California Multimedia Communications.